Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT05087667
Recruiting Not applicable

Study of the Effectiveness of a Polymer Cerclage System Compared to Cerclages Used in Standard Care (CERCPMCF) )

NCT05087667 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2022-03-08
Last updated
2025-03-20

Condition(s) studied

Femoral Fracture

Investigational drug(s) / intervention(s)

Implantation of Ortholoop cerclageImplantation of Cerclage used in current practice

Implantation of Ortholoop cerclage: implantation of Sterile Self Locking Polymer Cerclage System named OrthoLoop to the patient and follow up for 36 months post-intervention

Implantation of Cerclage used in current practice: implantation of Cerclage used in current practice to patients and follow up for 36 months post-intervention

Study summary

The use of cerclage wiring in the management of long bone fractures is common. With the increase in the placement of total hip ans shoulder prostheses, the occurrence of peri-prosthetic hip an shoulder fractures is also increasing, notably due to an older population.

Whether it is for a fracture on a native femur or humerus, or on a periprosthetic hip or shoulder fracture, the use of cerclage wiring is an adjuvant additional but not the main means to ensure stable osteosynthesis, allowing re-loading and early rehabilitation of patients. This method has demonstrated its ability to improve the fixation of this fracture type, associated with osteosynthesis or hip/shoulder prosthesis revision surgery. However, metal cerclage expose to a risk of metallosis which can compromise bone fusion, injury to neighboring soft parts causing pain and also injury to the surgical team when handling them. More recently, non-metallic cerclage have been developed and could overcome certain risks associated with metallic cerclage, while ensuring their bone fixing capacity and therefore bone consolidation. Indeed, non-metallic cerclage could withstand similar or even greater stresses than metallic cables, in particular concerning their resistance to rupture.

The "Sterile Self Locking Polymer Cerclage System" named OrthoLoop is a polymer cerclage which has been developed and could be used in these indications.

Thus, this study (SERRE) aims to investigate the clinical results and sequelae of adjuvant cerclage wires OrthoLoop Cerclage in the management of rehabilitation, per prosthetic or primary femoral or humeral fractures compared with cerclages system used in standard care.

SERRE is a 36 months follow up study in two arms :

* Experimental group: "OrthoLoop cercalge"
* Control group: "cerclages used in standard care" After each surgery, the patient follow-up period is 36 months. with 4 planned consultation visits after surgery at 6-8 weeks, 3, 6 and 36 months, with collection and measurement of the endpoints.

The main objective of this study is to assess the role of "OrthoLoop cerclage" of COUSIN Biotech in comparison with cerclages (metallic for the majority) used in standard care ; in the optimization of the consolidation of primary and periprosthetic femoral or humeral fractures, 6 months after surgery.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * patient with femoral or humeral fracture requiring the installation of one or more cerclage(s) and respecting at least one of the criteria below: * Primary femoral or humeral fractures (diaphyseal, metaphyseal, epiphyseal proximal or distal) with osteosynthesis by plate and screw or osteosynthesis by Intramedullary nailing associated with the installation of one or more cerclage(s) * Patients with traumatic fracture of femur or humerus that required prosthetic rehabilitation associated with the installation of one or more cerclage(s) * Peri-prosthetic fracture of the femur or humerus * Resumption of prosthesis (hip, knee, shoulder, elbow) requiring the installation of one or more cerclages * who underwent fixation with cerclage wiring (Sterile Self Locking Polymer Cerclage System or other cerclage systems used in standard care) * age ≥18 years * Who have given free, informed and written consent to participate in the study * Patient able to communicate in French * Patient affiliated to a social security system or entitled to a social security system Exclusion Criteria: * high-energy injury, * associated damage to other long bones, * fracture extension to the articular surface with displacement * Severe disease that could interfere with the study results or be life threatening * Patients with an infection * Allergy to any component of the medical products * Pregnant or breastfeeding women * Anticipated unavailability during the study * Participation in a clinical trial within 3 months prior to the inclusion visit. * Patient with linguistic or psychological incapacity to understand and sign the informed consent. * Patient deprived of liberty by administrative or judicial decision, or being under guardianship.

Primary outcome measure(s)

Trial sites (15)

FacilityCityRegionStatus
Clinique ESQUIROL SAINT HILAIRE Agen France Recruiting
Hôpital Privé Francheville Périgueux France Not Yet Recruiting
CH Tourcoing Tourcoing France Active Not Recruiting
CHU Lille Lille Nord Recruiting
CH Agen Agen France Recruiting
CH Arcachon Arcachon France Active Not Recruiting
Clinique de Saint Omer Blendecques France Recruiting
CH Le Mans Le Mans France Recruiting
CH Libourne Libourne France Recruiting
Ch Metz - Thionville Metz France Recruiting
CHRU Nancy Nancy France Recruiting
CHU Nimes Nîmes France Terminated
Polyclinique Du Parc Saint-Saulve France Recruiting
CHU Toulouse Toulouse France Terminated
CH Valenciennes Valenciennes France Recruiting

More Quanta Medical trials in France

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05087667 on ClinicalTrials.gov ↗ ← All trials in France